BOSTON & SYDNEY--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX:GID), a medical device company that has developed an innovative device to improve outcomes for patients diagnosed with type 2 diabetes and obesity, announces today that the board of directors has received the resignation of GI Dynamics non-executive director Mike Carusi of Advanced Technology Ventures (ATV) and Lightstone Ventures (LSV).

“Mike has served on the board of GI Dynamics since 2004, and we thank him for his significant contributions and many years of service,” said Dan Moore, chairman of the board.

“After more than a decade serving as a director, and in light of my other numerous commitments with ATV and LSV, I have decided to step down from the board of GI Dynamics,” said Carusi. “I wish the team future success as the company advances to the next chapter. I remain optimistic about the potential for EndoBarrier® as an important treatment option for patients with type 2 diabetes and obesity.”

About GI Dynamics

GI Dynamics, Inc. (ASX:GID), is the developer of EndoBarrier, the first endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit www.gidynamics.com.